NCT02392026 is a Phase 4 clinical trial of Metronidazole Gel in Vaginosis, Bacterial, sponsored by Insud Pharma.

Who is sponsoring NCT02392026?

NCT02392026 is sponsored by Insud Pharma.

What drugs are being tested in NCT02392026?

Interventions in NCT02392026: Metronidazole Gel.

What condition does NCT02392026 study?

NCT02392026 studies Vaginosis, Bacterial.

Is NCT02392026 still recruiting?

NCT02392026 is currently completed. Last updated 15 August 2023.

Last reviewed 2023-08-15 · How we verify

NCT02392026

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Tolerability of Metronidazole Gel 1.3%

Completed Phase 4 Last updated 15 August 2023

What this trial tests

Phase 4 trial testing Metronidazole Gel in Vaginosis, Bacterial in 60 participants. Completed in 5 October 2016.

Timeline

12 August 2015

Primary endpoint
5 October 2016

5 October 2016

Quick facts

Lead sponsor	Insud Pharma
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	12 August 2015
Primary completion	5 October 2016
Estimated completion	5 October 2016
Sites	8 locations across United States

Drugs / interventions tested

Metronidazole Gel

Conditions studied

Vaginosis, Bacterial — all drugs for Vaginosis, Bacterial →

Sponsor

Insud Pharma — full company profile →

Who can join

Adults 12 to 17, female only, with Vaginosis, Bacterial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal Gel in females 12 to \<18 years for the treatment of bacterial vaginosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Insud Pharma trials

Trials by the same sponsor.

NCT06968481 — Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage · Phase 2 · not yet recruiting
NCT05461573 — Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females · Phase 3 · completed
NCT05993143 — Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50 · Phase 3 · terminated
NCT03945513 — A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles · Phase 3 · completed
NCT04024163 — Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02392026 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Insud Pharma
Last refreshed: 15 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02392026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing